PSTV Swings to Profit on Derivative Gains, Boosts Liquidity

TL;DR

**PSTV's quarterly profit is a mirage from derivative gains, but their cash position is finally looking healthier, making it a speculative buy for the brave.**

AI Summary

PLUS THERAPEUTICS, INC. (PSTV) reported a significant turnaround in net income for the three months ended June 30, 2025, reaching $5.151 million, a substantial improvement from a net loss of $2.940 million in the prior-year period. This positive shift was primarily driven by a $6.512 million change in the fair value of derivative instruments, compared to $4.694 million in the same quarter of 2024. However, for the six months ended June 30, 2025, the company posted a net loss of $12.250 million, widening from a $6.201 million net loss in the comparable 2024 period, largely due to a negative change in fair value of derivative instruments of $2.631 million and $3.061 million in financing expenses. Grant revenue saw a modest increase to $1.390 million for the three months ended June 30, 2025, up from $1.279 million in 2024, but decreased for the six-month period to $2.449 million from $2.956 million. Research and development expenses decreased significantly by 55% to $1.246 million for the three months and by 45.8% to $3.002 million for the six months ended June 30, 2025, reflecting a more focused approach. The company's cash and cash equivalents dramatically increased to $2.233 million as of June 30, 2025, from $76 thousand at December 31, 2024, bolstered by $15.201 million in net cash provided by financing activities during the six-month period. Total current assets also rose to $9.214 million from $5.259 million, while total current liabilities decreased to $7.316 million from $15.551 million, improving the company's liquidity position.

Why It Matters

This 10-Q reveals a mixed financial picture for PLUS THERAPEUTICS, INC., with a quarterly profit driven by non-operating gains masking a wider year-to-date loss. For investors, the significant increase in cash and cash equivalents to $2.233 million and the reduction in current liabilities to $7.316 million are crucial, indicating improved short-term financial stability. The substantial decrease in R&D expenses could signal a more streamlined pipeline or a pause in certain development activities, which could impact future product offerings and competitive standing against larger biopharmaceutical firms. Employees might see this as a period of strategic recalibration, while customers and the broader market will be watching for sustained operational profitability and progress in their CNSide Cerebrospinal Fluid Tumor Cell Enumeration test.

Risk Assessment

Risk Level: high — Despite a quarterly net income of $5.151 million, the company reported a net loss of $12.250 million for the six months ended June 30, 2025, and has an accumulated deficit of $505.729 million. The positive quarterly net income was primarily due to a $6.512 million change in the fair value of derivative instruments, which is a non-operating, volatile item, rather than core business profitability. The company's ability to continue as a going concern remains a significant risk, as highlighted by its historical losses and reliance on financing activities.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence. While the improved cash position and reduced current liabilities are positive, the reliance on non-operating gains for quarterly profit and the substantial accumulated deficit suggest high operational risk. Consider this a highly speculative investment, focusing on future clinical trial results and sustainable revenue generation, not just one-off financial adjustments.

Financial Highlights

debt To Equity

N/A

revenue

$1.390M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$5.151M

eps

N/A

gross Margin

N/A

cash Position

$2.233M

revenue Growth

+9.5%

Revenue Breakdown

Key Numbers

• $5.151M — Net Income (For Q2 2025, a swing from a $2.940M loss in Q2 2024, primarily due to derivative gains.)
• $12.250M — Net Loss (For the six months ended June 30, 2025, widening from a $6.201M loss in the prior year.)
• $2.233M — Cash and Cash Equivalents (As of June 30, 2025, a significant increase from $76K at December 31, 2024.)
• $15.201M — Net Cash from Financing (Provided during the six months ended June 30, 2025, bolstering liquidity.)
• $6.512M — Change in Fair Value of Derivative Instruments (Positive impact on Q2 2025 net income.)
• $3.002M — Research and Development Expenses (For the six months ended June 30, 2025, a 45.8% decrease from $5.536M in 2024.)
• $7.316M — Total Current Liabilities (As of June 30, 2025, a decrease from $15.551M at December 31, 2024.)
• $505.729M — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses.)
• 99,264,526 — Shares Outstanding (As of August 8, 2025, indicating potential dilution.)
• $1.390M — Grant Revenue (For the three months ended June 30, 2025, a slight increase from $1.279M in 2024.)

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant
• Nasdaq Capital Market (regulator) — Exchange where common stock is registered
• U.S. Food and Drug Administration (regulator) — Regulatory body for product approvals
• European Medicines Agency (regulator) — Regulatory body for product approvals
• Lincoln Park Purchase Agreement (company) — Source of common stock issuance
• $5.151 million (dollar_amount) — Net income for the three months ended June 30, 2025
• $2.940 million (dollar_amount) — Net loss for the three months ended June 30, 2024
• $12.250 million (dollar_amount) — Net loss for the six months ended June 30, 2025
• $2.233 million (dollar_amount) — Cash and cash equivalents as of June 30, 2025
• $76 thousand (dollar_amount) — Cash and cash equivalents as of December 31, 2024

FAQ

Risk Factors

• FDA and EMA Approval Uncertainty [high — regulatory]: The company's product candidates are subject to rigorous review by regulatory bodies like the FDA and EMA. Delays or failure to obtain approval for product candidates, such as those in clinical trials, could significantly impact future revenue and market access.
• Significant Accumulated Deficit [high — financial]: As of June 30, 2025, the company has an accumulated deficit of $505.729M. This indicates a history of substantial losses, raising concerns about long-term financial viability and the need for continued funding.
• Competition in the Pharmaceutical Market [medium — market]: The company faces competition from other companies developing similar therapies and existing treatments. The market for its product candidates may be limited by the availability of alternative solutions and the success of competitors' development efforts.
• Reliance on Clinical Trial Success [high — operational]: The success of the company's product candidates hinges on positive outcomes from pre-clinical and clinical studies. Unfavorable results regarding efficacy or safety could halt development and impact the company's pipeline.
• Dependence on Financing Activities [medium — financial]: The company's substantial increase in cash ($2.233M as of June 30, 2025) was bolstered by $15.201M in net cash from financing activities in the first six months of 2025. This highlights a reliance on external funding, which may not always be available.
• Nasdaq Listing Standards Compliance [medium — regulatory]: The company intends to regain and maintain compliance with Nasdaq listing standards. Failure to do so could result in delisting, negatively impacting liquidity and investor confidence.
• Fair Value of Derivative Instruments Volatility [medium — financial]: The company's net income is significantly influenced by the fair value of derivative instruments. A positive change of $6.512M contributed to Q2 2025 net income, but a negative change of $2.631M impacted the six-month results, indicating potential earnings volatility.

Industry Context

PLUS THERAPEUTICS operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sector. The industry is characterized by long development cycles, significant regulatory hurdles, and the need for substantial R&D investment. Success is often driven by innovation in drug discovery, clinical trial outcomes, and securing regulatory approvals.

Regulatory Implications

The company's operations are heavily influenced by regulatory bodies such as the FDA and EMA. Obtaining and maintaining approvals for its product candidates is critical. Compliance with Nasdaq listing standards is also a key regulatory concern that could impact its ability to raise capital and its stock's liquidity.

What Investors Should Do

1. Monitor R&D Spending and Pipeline Progress
2. Analyze Derivative Instrument Impact
3. Assess Cash Burn and Future Funding Needs
4. Evaluate Competitive Landscape and Market Adoption

Key Dates

• 2025-06-30: End of Second Quarter and Six-Month Period — Reporting period for the financial results, showing a net income swing in Q2 but a widening net loss over six months, alongside improved liquidity.
• 2025-08-08: Shares Outstanding Record Date — Indicates 99,264,526 shares outstanding, relevant for per-share calculations and potential dilution analysis.

Glossary

Derivative Instruments

Financial contracts whose value is derived from an underlying asset, index, or rate. Changes in their fair value can significantly impact a company's reported earnings. (A substantial positive change in the fair value of derivative instruments ($6.512M) significantly boosted net income in Q2 2025, highlighting their impact on financial results.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any cumulative net income. It represents the total historical losses that have not been offset by profits. (The company's accumulated deficit of $505.729M as of June 30, 2025, underscores its history of unprofitability and potential need for ongoing capital.)

Grant Revenue

Revenue recognized from grants, typically from government agencies or foundations, often for research and development purposes. (Grant revenue is a source of funding for the company, with a slight increase noted for Q2 2025 ($1.390M) compared to the prior year.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A significant decrease in R&D expenses (55% for Q2, 45.8% for six months) suggests a more focused strategy or a shift in development priorities.)

Year-Over-Year Comparison

Compared to the prior year, PLUS THERAPEUTICS has shown a significant turnaround in quarterly net income, swinging from a loss of $2.940M in Q2 2024 to a gain of $5.151M in Q2 2025, largely due to favorable changes in derivative instrument valuations. However, for the six-month period, the net loss has widened from $6.201M to $12.250M, impacted by negative derivative fair value changes and financing expenses. Research and development expenses have seen a substantial reduction, indicating a more focused approach. Liquidity has dramatically improved, with cash and cash equivalents increasing to $2.233M from $76K, supported by strong financing inflows, and current liabilities have decreased significantly.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PSTV Nasdaq Capital Market Indica

Filing Documents

• pstv-20250630.htm (10-Q) — 2527KB
• pstv-ex10_15.htm (EX-10.15) — 183KB
• pstv-ex31_1.htm (EX-31.1) — 15KB
• pstv-ex31_2.htm (EX-31.2) — 12KB
• pstv-ex32_1.htm (EX-32.1) — 17KB
• 0000950170-25-108874.txt ( ) — 9887KB
• pstv-20250630.xsd (EX-101.SCH) — 1278KB
• pstv-20250630_htm.xml (XML) — 1621KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 6. Exhibits 43 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") and the exhibits incorporated herein by reference contain "forward-looking statements" which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements other than statements of historical fact constitute "forward-looking statements." These forward-looking statements do not constitute guarantees of future performance. These forward-looking statements may be identified by terms such as "intend," "expect," "project," "believe," "anticipate," "initiate," "will," "should," "would," "could," "may," "designed," "potential," "evaluate," "hypothesize," "plan," "progressing," "proceeding," "exploring," "opportunity," "hopes," "suggest," and similar expressions, or the negative of such expressions. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses; our intent to regain and maintain compliance with Nasdaq listing standards; our strategic collaborations and license agreements, intellectual property, U.S. Food and Drug Administration and European Medicines Agency approvals and interactions and government regulation; the potential size of the market for our product candidates; our research and development efforts; results from our pre-clinical and clinical studies and the implications of such results regarding the efficacy or safety of our

FINANC IAL INFORMATION

PART I. FINANC IAL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements PLUS THERAPEUTICS, INC. CONDEN SED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and par value data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 2,233 $ 76 Investments 4,646 3,530 Grant receivable 1,021 571 Other current assets 1,314 1,082 Total current assets 9,214 5,259 Property and equipment, net 289 448 Operating lease right-use-of assets 29 73 Goodwill 372 372 Intangible assets, net 401 469 Other assets 45 12 Total assets $ 10,350 $ 6,633 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 6,359 $ 11,288 Operating lease liability 30 44 Deferred grant liability 927 927 Line of credit — 3,292 Total current liabilities 7,316 15,551 Noncurrent operating lease liability — 31 Total liabilities 7,316 15,582 Commitments and contingencies (Note 7) Stockholders' equity (deficit): Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.001 par value; 2,000,000,000 shares authorized; 92,438,432 shares issued; and 92,180,007 shares outstanding as of June 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively 92 6 Treasury stock (at cost), 258,425 shares as of June 30, 2025 and December 31, 2024, respectively ( 500 ) ( 500 ) Additional paid-in capital 509,171 485,024 Accumulated deficit ( 505,729 ) ( 493,479 ) Total stockholders' equity (deficit) 3,034 ( 8,949 ) Total liabilities and stockholders' equity $ 10,350 $ 6,633 See Accompanying Notes to these Condensed Consolidated Financial Statements 4 PLUS THERAPEUTICS, INC. C

View Full Filing

View this 10-Q filing on SEC EDGAR